OverviewSuggest Edit

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Its lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective allowing therapies to reach the tumor. 
In addition to the Company's proprietary product portfolio, Halozyme has value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for its ENHANZE drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. 

TypePublic
Founded1998
HQSan Diego, US
Websitehalozyme.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Feb 2020)132(-53%)
Job Openings7
Revenue (FY, 2019)$196 M(+30%)
Share Price (Jul 2020)$28.5
Cybersecurity ratingCMore

Key People/Management at Halozyme Therapeutics

Helen Torley

Helen Torley

President, Chief Executive Officer and member of the Board of Directors
Laurie D. Stelzer

Laurie D. Stelzer

Senior Vice President & Chief Financial Officer
Mas Matsuda

Mas Matsuda

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Michael J. LaBarre

Michael J. LaBarre

Senior Vice President, Chief Technical Officer
Steve Knowles

Steve Knowles

Chief Medical Officer
Todd Butler

Todd Butler

Chief of Staff to the CEO, Vice President, Head of Project Management
Show more

Halozyme Therapeutics Office Locations

Halozyme Therapeutics has an office in San Diego
San Diego, US (HQ)
11388 Sorrento Valley Rd
Show all (1)

Halozyme Therapeutics Financials and Metrics

Halozyme Therapeutics Revenue

Embed Graph
View revenue for all periods
Halozyme Therapeutics's revenue was reported to be $195.99 m in FY, 2019
USD

Revenue (Q1, 2020)

25.4m

Gross profit (Q1, 2020)

19.6m

Gross profit margin (Q1, 2020), %

77.2%

Net income (Q1, 2020)

(6.1m)

EBIT (Q1, 2020)

(3.2m)

Market capitalization (3-Jul-2020)

3.9b

Closing stock price (3-Jul-2020)

28.5

Cash (31-Mar-2020)

104.8m

EV

4.2b
Halozyme Therapeutics's current market capitalization is $3.9 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

56.1m42.3m54.8m75.3m135.1m146.7m316.6m151.9m196.0m

Revenue growth, %

37%79%9%

Cost of goods sold

257.8k1.1m6.2m22.7m29.2m33.2m31.2m10.1m45.5m

Gross profit

55.8m41.2m48.6m52.6m105.8m113.5m285.5m141.7m150.4m
USDQ2, 2011

Financial Leverage

4.5 x
Show all financial metrics

Halozyme Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

Halozyme Therapeutics Online and Social Media Presence

Embed Graph

Halozyme Therapeutics News and Updates

Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference

PT / 11:30 a.m. ET. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.read more

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible senior notes...

Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 at 10:30 a.m....

Halozyme Therapeutics To Participate In Upcoming Investor Conference

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the 2018 Cantor Global Healthcare Conference in New York on Monday, October 1 at 3:30 p.m. ET/12:30 p.m....

Halozyme Therapeutics To Participate In Upcoming Healthcare Conference

SAN DIEGO, July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Canaccord Genuity 38th Annual Growth Conference in Boston on Thursday, August 9 at 12:00 p.m....
Show more

Halozyme Therapeutics Frequently Asked Questions

  • When was Halozyme Therapeutics founded?

    Halozyme Therapeutics was founded in 1998.

  • Who are Halozyme Therapeutics key executives?

    Halozyme Therapeutics's key executives are Helen Torley, Laurie D. Stelzer and Mas Matsuda.

  • How many employees does Halozyme Therapeutics have?

    Halozyme Therapeutics has 132 employees.

  • What is Halozyme Therapeutics revenue?

    Latest Halozyme Therapeutics annual revenue is $196 m.

  • What is Halozyme Therapeutics revenue per employee?

    Latest Halozyme Therapeutics revenue per employee is $1.5 m.

  • Who are Halozyme Therapeutics competitors?

    Competitors of Halozyme Therapeutics include Progenics Pharmaceuticals, Verastem and Sesen Bio.

  • Where is Halozyme Therapeutics headquarters?

    Halozyme Therapeutics headquarters is located at 11388 Sorrento Valley Rd, San Diego.

  • Where are Halozyme Therapeutics offices?

    Halozyme Therapeutics has an office in San Diego.

  • How many offices does Halozyme Therapeutics have?

    Halozyme Therapeutics has 1 office.